Newsroom
Sorted by: Latest
-
Dicamba Herbicide Market Sizing and Opportunity Forecast 2025-2032 with Regional Outlooks Featuring Bayer, Syngenta, Corteva, BASF, FMC and More - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Dicamba Herbicide Market - Global Forecast 2025-2032" report has been added to ResearchAndMarkets.com's offering. The Dicamba Herbicide Market is navigating significant transformation, fueled by ongoing regulatory shifts, advances in application technology, and the critical focus on sustainability among senior agrochemical decision-makers. The ability to translate complex trends into practical strategies gives industry leaders the edge in an increasingly dynamic se...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust FactorFX UCITS ETF 24.12.2025 FTFX IE00BD5HBQ97 63,402.00 USD 1,630,900.07 25.723 ...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest US Equity Max Buffer UCITS ETF - December 24.12.2025 MDEC.LN IE0007FIJUO5 50,002.00 USD 1,371,639.33 27.432 ...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Equity Income UCITS ETF 24.12.2025 UINC IE00BZBW4Z27 10,104,154.00 USD 352,551,843.10 34.892 ...
-
Ooma Completes Acquisition of Phone.com
SUNNYVALE, Calif.--(BUSINESS WIRE)--Ooma, Inc., a smart communications platform for businesses and consumers, today announced the successful closing of its previously announced acquisition of Phone.com, a provider of cloud-based business communications for small and medium-sized organizations, for approximately $23.2 million in cash, subject to customary working capital adjustments. Phone.com is expected to generate $22-$23 million in revenue and $1.0-$1.5 million in adjusted EBITDA annually, b...
-
BGC Group Updates its Outlook for the Fourth Quarter of 2025
NEW YORK--(BUSINESS WIRE)--BGC Group, Inc. (Nasdaq: BGC), today announced that it has updated its outlook for the quarter ending December 31, 2025. Updated Outlook BGC reaffirmed its previously stated outlook ranges for revenue and pre-tax Adjusted Earnings for the fourth quarter of 2025. The Company’s outlook was contained in BGC’s financial results press release issued on November 6, 2025, which can be found at http://ir.bgcg.com. Non-GAAP Financial Measures The non-GAAP definitions below inc...
-
Nicokick and Northerner Close Out 2025 with Unwavering Commitment to Responsible Online Retailing
WASHINGTON--(BUSINESS WIRE)--Nicokick and Northerner, leading online retailers for nicotine pouches and modern oral products in the United States, reaffirmed their commitment to setting and maintaining the highest standard for responsible, compliant, and transparent online retailing of nicotine pouches for adults aged 21 and over. This announcement comes in light of the U.S. Food and Drug Administration’s recent announcements that outline a clearer path for regulation and category standards. Th...
-
Establishment Labs Submits to FDA for Approval of Motiva Implants in Breast Reconstruction
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that it has submitted Motiva® implants for approval in primary and revision breast reconstruction to the U.S. Food and Drug Administration (FDA). The products were previously approved by the FDA for use in breast augmentation on September 27, 2024. “Expanding our FD...
-
Enveric Biosciences Announces Patent Issuance
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced the issuance of U.S. Patent No. 12,492,179 entitled, “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives” (the “‘179 patent”), with claims to compositions and methods of treatment for novel molecules with the potential to be developed...
-
Robbins Geller Rudman & Dowd LLP Announces Pending Class Action Lawsuit in the ExxonMobil Securities Litigation
SAN DIEGO--(BUSINESS WIRE)--The following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the ExxonMobil Securities Litigation: UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF TEXAS DALLAS DIVISION PEDRO RAMIREZ, JR., Individually and on Behalf of All Others Similarly Situated, Civil Action No. 3:16-cv-03111-K CLASS ACTION Plaintiff, vs. EXXON MOBIL CORPORATION, et al., Defendants. SUMMARY NOTICE OF PENDENCY OF CLASS ACTION TO: ALL PER...